Vaccinations in psychiatry;Vaccinaties in de psychiatrie

Tijdschrift voor Psychiatrie

Volumn 51, Issue 10, 2009, Pages 751-759

  Dols, A ^a   Van Den Brink, W ^b,c   Eikelenboom, P ^b,d,e  

^a GGZ InGeest   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

^d GGZ BuitenAmstel ^*  (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Cocaine; Immunotherapy; Prevention; Vaccination

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; IMMUNOMODULATING AGENT; RECOMBINANT VACCINE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; COCAINE DEPENDENCE; COGNITION; DRUG WITHDRAWAL; HUMAN; PROTEIN AGGREGATION; REVIEW; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; ANTIBODIES; HUMANS; IMMUNOTHERAPY; SUBSTANCE-RELATED DISORDERS; VACCINATION;

EID: 70350347732     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Baird, G., Pickles, A., Simonoff, E., e.a. (2008). Measles vaccination and antibody response in autism spectrum disorders. Archives of Disease in Childhood, 93, 832-837.
2. Bayer, A.J., Bullock, R., Jones, R.W., e.a. (2005). Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology, 64, 94-101.
3. Benner, R., van Blokland, S.C.A., van Dongen, J.J.M., e.a. (2003). Medische immunologie. (2de druk). Maarssen: Reed Business.
4. Bishop, G.M., Robinson, S.R., Smith, M.A., e.a. (2002). Call for Elan to publish Alzheimer's trial details. Nature, 416, 677.
5. Boche, D., & Nicoll, J.A.R. (2008). The role of the immune system in clearence of Aβ from the brain. Brain Pathology, 18, 267-278.
6. Brendza, R.P., & Holtzman, D.M. (2006). Amyloid-β immunotherapies in mice and men. Alzheimer Disease and associated disorders, 20, 118-123.
7. Brink, W. van den, & van Ree, J.M. (2003). Pharmacological treatments for heroin and cocaine addiction. European Neuropsychopharmacology, 13, 476-487.
8. Brody, D.L., & Holtzman, D.M. (2008). Active and passive immunotherapy for neurodegenerative disorders. Annual Review of Neuroscience, 31, 175-193.
9. Carrera, M.R.A., Ashley, J.A., Parsons, L.H., e.a. (1995). Suppression of psychoactive effects of cocaine by active immunization. Nature, 378, 727-730.
10. Carrera, M.R.A., Ashley, J.A., Zhou, B., e.a. (2000). Cocaine vaccines: antibody protection against relapse in a rat model. Proceedings of the National Academy of Sciences of the United States of America, 97, 6202-6206.
11. Cerny, T. (2005). Anti-nicotine vaccination: where are we? Recent Results in Cancer Research, 166, 167-175.
12. Check, E. (2002). Nerve inflammation halts trial for Alzheimer's drugs. Nature, 415, 462.
13. Dodel, R.C., Du, Y., Depboylu, C., e.a. (2004). Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 75, 1472-1474.
14. Dols, A. (2004). Immunotherapy strategies in breast cancer and melanoma. (Proefschrift). Amsterdam: Thela Thesis.
15. Elkashef, A., Biswas, J., Acri, J.B., e.a. (2007). Biotechnology and the treatment of addictive disorders: new opportunities. Biodrugs, 21, 259-267.
16. Fluitman, S.B.A.H.A., Westenberg, H.G.M., & Denys, D.A.J.P. (2004). PANDAS. Een verband tussen infectie en psychopathologie. Tijdschrift voor Psychiatrie, 46, 755-761.
17. Fox, B.S., Kantak, K.M., Edwards, M.A., e.a. (1996). Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Medicine, 2, 1129-1132.
18. Gilman, S., Koller, M., Black, R.S., e.a. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 64, 1553-1562.
19. Haney, M., & Kosten, T.R. (2004). Therapeutic vaccines for substance dependence. Expert Review of Vaccines, 3, 11-18.
20. Hock, C., Konietzko, U., Papassotiropoulos, A., e.a. (2002). Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nature Medicine, 8, 1270-1275.
21. Holmes, C., Boche, D., Wilkinson, D., e.a. (2008). Long-term effects of Aβ42 immunization in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase I trial. Lancet, 372, 216-223.
22. Horton, R. (2004). A statement by the editors of The Lancet. Lancet, 363, 820-821.
23. Hyman, B.T., Smith, C., Buldyrev, I., e.a. (2001). Autoantibodies to amyloid-beta and Alzheimer's disease. Annals of Neurology, 49, 808-810.
24. Janeway, C.A., & Travers, P. (1997). Immunobiology; the immune system in health and disease. (3de druk). New York: Garland.
25. Kantak, K.M., Collins, S.L., Lipman, E.G. (2000). Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology, 148, 251-262.
26. Kosten, T.R., Rosen, M., Bond, J., e.a. (2002). Human therapeutic cocaine vaccine: safety and immunogenecity. Vaccine, 20, 1196-1204.
27. Maas, D.W., Westendorp, R.G.J., & van der Mast, R.C. (2008). Immuunactivatie en depressie bij ouderen. Nederlands Tijdschrift voor Geneeskunde, 152, 1413-1417.
28. Maier, M., Seabrook, T.J., & Lemere, C.A. (2005). Developing novel immunogens for an effective, safe Alzheimer's disease vaccine. Neurodegenerative Disease, 2, 267-272.
29. Martell, B.A., Mitchell, E., Poling, J., e.a. (2005). Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry, 58, 158-164.
30. Mohajeri, M.H. (2007). The underestimated potential of the immune system in prevention of Alzheimer's disease pathology. BioEssays, 29, 927-932.
31. Morgan, D., Diamond, D.M., Gottschall, P.E., e.a. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408, 982-985.
32. Morgan, D. (2006). Immunotherapy for Alzheimer's disease. Journal of Alzheimer's disease, 425-432.
33. Murch, S.H., Anthony, A., Casson, D.H., e.a. (2004). Retraction of an interpretation. Lancet, 363, 750.
34. Maurer, P., & Bachmann, M.F. (2007). Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opinion on Investigational Drugs, 16, 1775-1783.
35. Nicoll, J.A.R., Wilkinson, D., Holmes, C., e.a. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-peptide: a case-report. Nature Medicine, 9, 448-452.
36. Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., e.a. (2003). Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology, 61, 46-54.
37. Orson, F.M., Kinsey, B.M., Singh, R.A.K., e.a. (2007). The future of vaccines in the management of addictive disorders. Current Psychiatry Reports, 9, 381-387.
38. Relkin, N.R., Szabo, P., Adamiak, B., e.a. (2008). 18-Month study of intravenous immunoglobin for treatment of mild Alzheimer disease. Neurobiology of Aging, (ter perse). doi:10.1016/j.neurobiolaging.2007.12.021.
39. Schenk, D., Barbour, R., Dunn, W., e.a. (1999). Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173-177.
40. Solomon, B. (2006). Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination. Journal of Alzheimer's disease, 9, 433-438.
41. Vasilevko, V., & Cribbs, D.H. (2006). Novel approaches for immunotherapeutic interventions in Alzheimer's disease. Neurochemistry International, 49, 113-126.
42. Wakefield, A.J., Murch, S.H., Anthony, A., e.a. (1998). Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet, 351, 637-641.
43. Wilcock, D.M., Dicarlo, G., Henderson, D., e.a. (2003). Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. Journal of Neuroscience, 23, 3745-3751.